Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive’s global mix of toothpaste, dish soap, and veterinarian-recommended pet food produces disclosures that touch everything from raw material costs to emerging-market currency swings. If you are looking for Colgate-Palmolive insider trading Form 4 transactions or need the Hill’s Pet Nutrition margin story inside a 300-page report, this page delivers every document the second it lands on EDGAR.
Our AI engine turns dense text into plain language, so Colgate-Palmolive SEC filings explained simply is more than a promise. Scan an annual report 10-K simplified to see Continental Europe toothbrush share in seconds, or open a quarterly earnings report 10-Q filing and jump straight to pricing elasticity tables. Real-time alerts flag Colgate-Palmolive Form 4 insider transactions real-time, helping you track executive stock transactions Form 4 before markets react. When management announces factory upgrades, our platform tags the related 8-K material events explained and highlights cap-ex impacts.
Every filing type is covered—10-K, 10-Q, 8-K, Form 4, S-8, and the proxy statement executive compensation that details CEO incentive metrics. Use AI-powered summaries, inline financial extractions, and side-by-side versions to compare periods. Whether you need a quick earnings report filing analysis or are understanding Colgate-Palmolive SEC documents with AI for a deep dive, Stock Titan replaces hours of manual reading with actionable clarity.
Colgate-Palmolive (NYSE: CL) submitted a routine Form 3 – Initial Statement of Beneficial Ownership for newly reported insider John Hazlin, Chief Growth Officer.
The filing shows Hazlin directly owns 14,385 common shares and indirectly owns 5,382 shares through the company’s 401(k) plan, for a total of 19,767 shares of common stock. In addition, he holds five separate stock-option grants covering an aggregate 103,340 underlying shares with exercise prices ranging from $72.83 to $106.34 and expiration dates between 2028 and 2032. Vesting schedules are disclosed for each grant, generally becoming exercisable in one-third increments starting one year after the grant date.
No purchases, sales or other transactions occurred on the reported event date (06/16/2025); the form simply establishes Hazlin’s beneficial ownership under Section 16(a). The filing contains no financial results, strategic updates, or other material corporate events.